Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Recent Advances in Prevention and Treatment of Infectious Diseases"
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".
Deadline for manuscript submissions: 31 December 2023 | Viewed by 9720
Special Issue Editors
Interests: biofilms; antimicrobial agents; protozoa; fungi; Candida; pathogenicity; drug resistance; combination therapy; mechanism of action; cytotoxicity; in vitro treatments; drug synergism
E-Mail Website1 Website2
Interests: fungi; Candida; protozoa; Acanthamoeba; Toxoplasma; pathogenicity; microbicidal agents; biofilms; drug resistance; combination therapy; in vitro susceptibility testing; cytotoxicity; Fractional Inhibitory Concentration (FIC) index; drug synergism
Interests: fungi; Candida; antifungal agents; biofilms; drug resistance; combination therapy; in vitro susceptibility testing; cytotoxicity; Fractional Inhibitory Concentration (FIC) index; drug synergism
Special Issue Information
Diseases caused by eukaryotic and prokaryotic microorganisms have a high prevalence and a worldwide distribution, causing millions of deaths every year. However, the antimicrobial agents of choice against some of these infections are limited (e.g., bacteriemia, malaria, candidiasis, leishmaniasis, toxoplasmosis, biofilm-related infections, amebiasis, keratitis, and bloodstream infections). In addition, the majority of therapeutic treatments are associated with microorganism resistance, severe side effects due to toxicity, or limited activity against the causative agent of the disease.
This Special Issue aims to assemble original research and review articles related to strategies to address the problems associated with these widely distributed infections; new advances in the development of effective strategies to control and treat microbial infections, including new therapeutic treatments, new targets and new diagnosis systems; mechanisms of action; new delivery systems or combined therapy to enhance election treatment efficacy; new formulations to improve tolerability, among others.
Dr. Irene Heredero-Bermejo
Prof. Dr. José Luis Copa Patiño
Dr. Natalia Gómez Casanova
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- infectious diseases
- opportunistic infections
- novel treatment
- diagnosis systems
- delivery systems
- biofilm-related infections